Mark Flather News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark flather. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Flather Today - Breaking & Trending Today

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 First Quarter Corporate Update Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded, Thursday, August 10, 2023. I would now like to turn the conference over to Mark […] ....

United States , Alexander Raths Shutterstock , Mark Flather , Residential Real Estate Stocks To Buy , Extremely Profitable Stocks , Social Anxiety Disorder , Shawn Singh , Mark Flather , Forward Looking Statement , Placebo Effect , Public Speaking ,

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2023 Earnings Call Transcript

Operator: Greetings. Welcome to VistaGen Therapeutics Third Quarter Fiscal Year 2023 Results Conference Call. At this time all participants are in a listen-only mode. ....

Shawn Singh , Andrew Tsai , Tim Lugo , Timothy Lugo , Jerrold Dotson , Jerry Dotson , William Blair , Mark Flather , Exchange Commission , Vistagen Therapeutics Inc , Pherin Pharmaceuticals , Vistagen Therapeutics , Call Transcript February , Vistagen Therapeutics Third Quarter Fiscal Year , Vice President , Chief Executive Officer , Chief Financial , Investors Events , One Mind , Social Anxiety Disorder , Label Study , Affamed Agreement ,

Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results

Pherin acquisition completed; all future royalty payment obligations related to PH94B and PH10 eliminated, three new drug candidates added to Vistagen’s pipelinePH94B Phase 3 program for social anxiety disorder advancing towards important next stepsPH10 Phase 1 study initiated to facilitate plans for Phase 2B develo. ....

United States , Shawn Singh , Nate Hitchings , Mark Flather , Company Phase , Pherin Pharmaceuticals , Drug Administration , Exchange Commission , International Number Toll , Acquisition Of Pherin Pharmaceuticals Inc , Pherin Pharmaceuticals Inc , Chief Executive Officer , Liebowitz Social Anxiety Scale , New Drug , Label Study , Fast Track , Probenecid Phase , Quarter Financial , Dial In Number , Annual Report , Quarterly Report , Seriesb Preferred , Investor Relations ,

Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023

Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Nate Hitchings , Mark Flather , Wall Street , Vistagen Fiscal Year , Quarter Results Conference Call , Toll Free , International Dial In , Investor Relations ,

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Shawn Singh , Nate Hitchings , Mark Flather , Exchange Commission , Company Current Report On Form , Pherin Pharmaceuticals Inc , Wall Street , Pherin Pharmaceuticals , Chief Executive Officer , Current Report , Annual Report , Quarterly Report , Investor Relations ,